price month
ep in-lin sale pre-
organ growth vs cs estimate sale bil
in-lin preliminari sale bil estim consensu
ep bottom line sale net cog non-op
incom lower tax partial off-set higher sg
 oper margin came in-lin cs estimate
guidanc compani guid organ sale growth
vs estim bottom-lin guid ep
includ dilut number recent deal
exclud accret btg compar estim
includ btg factset consensu
figur metric in-lin pre-releas
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
boston scientif corp global manufactur provid
medic devic equip area vascular intervent
structur heart men women health
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
sale
sale
sale
sale
estimate
ep
estimate
charl martineau pm univers toronto compani mention price
